Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354449 | 0.87 | FFAR1 (0.50) | GRM2FFAR1MEN1LMNAMAPT | |
| SCHEMBL4017548 | 0.83 | HSP90AB1 (0.49) | MEN1LMNAMAPTHPGDHTT | |
| SCHEMBL9821864 | 0.82 | PRKCI (0.44) | FFAR1PRKCIHSP90AB1 | |
| SCHEMBL7044950 | 0.82 | HPGD (0.49) | MEN1LMNAMAPTHPGDHTT | |
| SCHEMBL11393041 | 0.81 | MAPT (0.40) | GRM2MEN1LMNAMAPTHPGD | |
| SCHEMBL30736074 | 0.78 | CYP1A2 (0.50) | GRM2MEN1LMNAMAPTKMT2A | |
| SCHEMBL10726758 | 0.78 | SELL (0.53) | GRM2LMNAMAPTHPGDPRKCI | |
| SCHEMBL480388 | 0.78 | CYP1A2 (0.50) | GRM2MEN1LMNAMAPTKMT2A | |
| SCHEMBL6102044 | 0.78 | MEN1 (0.38) | GRM2MEN1LMNAMAPTHPGD | |
| SCHEMBL7968004 | 0.77 | HTT (0.55) | FFAR1MEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | MERCK & CO., INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | GRM2, GRM1, GRIK2 | GRM2 1/4885FFAR1 149/4885MEN1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.